DEM Biopharma

dembiopharma.com

DEM Bio Pharma is pioneering the next generation of immunotherapeutics aimed at harnessing the innate immune system to combat cancer. The company focuses on unleashing macrophages and other myeloid effector cells to eliminate tumors by targeting innovative 'don't eat me' (DEM) and 'eat me' (EM) signals on cancer cells. Utilizing their proprietary CHo MP™ platform, DEM Bio conducts systematic inter-cellular CRISPR screening to identify unexplored signals that can enhance immune response against tumors. Co-founded by notable scientists and backed by the Longwood Fund, DEM Bio is positioned at the forefront of immuno-oncology, aiming to deliver transformative therapies for cancer treatment.